IDYA - Ideaya Biosciences Inc logo

Ideaya Biosciences Inc

IDYA

Ideaya Biosciences develops targeted oncology therapeutics using precision medicine and molecular diagnostics. Its pipeline includes treatments for uveal melanoma, small cell lung cancer, and other tumors, supported by strategic collaborations with major pharmaceutical firms.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$1,514today

Score Overview

1 Year
Score
Net Growth-53.93%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth7.05%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score3.1
Net Growth-268.22%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth8x
Rev Trend60%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-355.28%
Net Trend29%
Net Income Consistency
Rev Growthโ€”
Rev Trend71%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Ideaya Biosciences Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. IDYA does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 34.71โ€”
1 Year2025-10-23
$ 28.4222.13%
5 Years2021-10-22
$ 22.9251.44%
All Time2019-05-23
$ 11.19210.19%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 234M-$ 175M$ 828M
2025$ 218M-$ 113M$ 639M
2024$ 7M-$ 274M$ 676M
2023$ 23M-$ 112M$ 525M
2022$ 50M-$ 54M$ 364M
2021$ 27M-$ 47M$ 246M
2020$ 19M-$ 32M$ 283M
IPO2019$ 0.00-$ 38M$ 98M
IDYA - Ideaya Biosciences Inc logo

Ideaya Biosciences Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 19M to $ 218M and net income went from -$ 32M to -$ 113M. Revenue increased in 3 of those 5 years; net income in 1.

Ideaya Biosciences Inc currently holds a 5-year HDB Score of 3.1 out of 10. How the HDB Score is calculated.

Membership

Explore IDYA with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies